Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
0.530
-0.011 (-2.11%)
At close: Mar 6, 2026, 4:00 PM EST
0.537
+0.007 (1.32%)
After-hours: Mar 6, 2026, 6:58 PM EST
Xilio Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Xilio Therapeutics stock has a target of 2.00, which predicts an increase of 277.36% from the current stock price of 0.53.
Analyst Consensus: Buy
* Price targets were last updated on Aug 6, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Xilio Therapeutics is "Buy". This means that the analyst believes this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Leerink Partners | Leerink Partners | Buy Initiates $2 | Buy | Initiates | $2 | +277.36% | Aug 6, 2025 |
| Raymond James | Raymond James | Buy Maintains $6 → $4 | Buy | Maintains | $6 → $4 | +654.72% | Nov 8, 2024 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +1,220.75% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +1,220.75% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +1,786.79% | Jan 27, 2023 |
Financial Forecast
Revenue This Year
46.11M
from 6.34M
Increased by 626.78%
Revenue Next Year
82.57M
from 46.11M
Increased by 79.08%
EPS This Year
-0.44
from -1.09
EPS Next Year
-0.18
from -0.44
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 47.9M | 85.8M | ||||
| Avg | 46.1M | 82.6M | ||||
| Low | 44.7M | 80.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 655.6% | 86.2% | ||||
| Avg | 626.8% | 79.1% | ||||
| Low | 605.2% | 73.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.46 | -0.19 | |
| Avg | -0.44 | -0.18 | |
| Low | -0.43 | -0.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.